Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates

分组1 - Precision BioSciences reported quarterly earnings of $0.36 per share, exceeding the Zacks Consensus Estimate of a loss of $0.21 per share, compared to a loss of $3.2 per share a year ago, representing an earnings surprise of +271.43% [1] - The company posted revenues of $34.2 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 178.08%, compared to year-ago revenues of $0.64 million [2] - Precision BioSciences shares have increased by approximately 21.6% since the beginning of the year, while the S&P 500 has declined by 1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.82 on revenues of $4.3 million, and for the current fiscal year, it is -$2.07 on revenues of $31.4 million [7] - The Medical - Biomedical and Genetics industry, to which Precision BioSciences belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]